Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.

Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ.

Urol Oncol. 2017 Feb 1. pii: S1078-1439(16)30371-4. doi: 10.1016/j.urolonc.2016.11.005. [Epub ahead of print]

PMID:
28161323
2.

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD.

Clin Genitourin Cancer. 2016 Dec 1. pii: S1558-7673(16)30337-8. doi: 10.1016/j.clgc.2016.11.001. [Epub ahead of print] No abstract available.

3.

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH.

Sci Rep. 2016 Dec;6(1):25. doi: 10.1038/s41598-016-0021-4.

4.

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.

Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP.

Clin Genitourin Cancer. 2016 Sep 8. pii: S1558-7673(16)30260-9. doi: 10.1016/j.clgc.2016.08.026. [Epub ahead of print]

PMID:
27771244
5.

The Effect of Enzalutamide and Bicalutamide on Patient-reported Quality of Life Outcomes: Results from the TERRAIN Study.

Tyson MD, Bryce A.

Eur Urol. 2016 Aug 17. pii: S0302-2838(16)30484-5. doi: 10.1016/j.eururo.2016.08.017. [Epub ahead of print] No abstract available.

PMID:
27544580
6.

Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.

Bryce AH, Antonarakis ES.

Int J Urol. 2016 Aug;23(8):646-53. doi: 10.1111/iju.13134. Review.

PMID:
27255944
7.

Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.

Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M.

BMJ Open. 2016 Apr 15;6(4):e010332. doi: 10.1136/bmjopen-2015-010332.

8.

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma.

Jain T, Bryce A.

Cureus. 2015 Dec 16;7(12):e410. doi: 10.7759/cureus.410.

9.

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH.

Cancer Immunol Res. 2015 Dec;3(12):1303-7. doi: 10.1158/2326-6066.CIR-15-0150.

10.

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.

Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP.

PLoS One. 2015 Jul 16;10(7):e0132831. doi: 10.1371/journal.pone.0132831.

11.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153.

12.

PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data.

Hart SN, Moore RM, Zimmermann MT, Oliver GR, Egan JB, Bryce AH, Kocher JP.

PeerJ. 2015 May 19;3:e970. doi: 10.7717/peerj.970.

13.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8.

PMID:
25795410
14.

Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.

Mangold AR, Bryce A, Sekulic A.

J Am Acad Dermatol. 2014 Nov;71(5):e205-6. doi: 10.1016/j.jaad.2014.03.043. No abstract available.

15.

Perioperative complications after neoadjuvant chemotherapy and radical cystectomy for bladder cancer.

Tyson MD 2nd, Bryce AH, Ho TH, Carballido EM, Castle EP.

Can J Urol. 2014 Jun;21(3):7259-65.

PMID:
24978354
16.

Genomic medicine and incidental findings: balancing actionability and patient autonomy.

McCormick JB, Sharp RR, Farrugia G, Lindor NM, Babovic-Vuksanovic D, Borad MJ, Bryce AH, Caselli RJ, Ferber MJ, Johnson KJ, Lazaridis KN, McWilliams RR, Murray JA, Parker AS, Schahl KA, Wieben ED.

Mayo Clin Proc. 2014 Jun;89(6):718-21. doi: 10.1016/j.mayocp.2014.04.008. No abstract available.

PMID:
24943691
17.

Shining a warm light on cryoglobulinemia.

Bryce A, Gertz M.

Oncology (Williston Park). 2013 Nov;27(11):1116, 1118. No abstract available.

18.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.

PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135.

19.

Current status and future directions of personalized medicine.

Bryce AH, McWilliams R.

Genome Med. 2013 Jul 29;5(7):62. doi: 10.1186/gm466.

20.

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.

Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P.

Invest New Drugs. 2012 Oct;30(5):1934-41. doi: 10.1007/s10637-011-9742-1.

Items per page

Supplemental Content

Loading ...
Support Center